Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.